SCHEMBL3759873

SCHEMBL3759873

O=C(Nc1[c]cccc1)c1ccon1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.41
PYGM P11217 1/20 0.40
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.37
RAPGEF3 O95398 1/20 0.36
RAPGEF4 Q8WZA2 1/20 0.36
HPGD P15428 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 2/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34
DRD2 P14416 1/20 0.34
DRD1 P21728 1/20 0.34
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759507 0.76 HDAC6 (0.51) SMN1; SMN2GAANPC1RAB9ALMNA
SCHEMBL6633619 0.76 POLB (0.58) SMN1; SMN2PYGMRAPGEF3RAPGEF4NPC1
SCHEMBL3756642 0.72 RIPK1 (0.35) SMN1; SMN2TSHRHPGDNPC1RAB9A
SCHEMBL6609769 0.72 RAB9A (0.58) SMN1; SMN2GAATSHRNPC1RAB9A
SCHEMBL429187 0.72 PTPN1 (0.48) SMN1; SMN2HPGDNPC1RAB9AMEN1
SCHEMBL6797998 0.72 RAB9A (0.61) SMN1; SMN2GAATSHRHPGDNPC1
SCHEMBL6607868 0.72 FAAH (0.41) SMN1; SMN2NPC1RAB9A
SCHEMBL31411895 0.71 NPC1 (0.61) SMN1; SMN2GAATSHRNPC1RAB9A
SCHEMBL9725165 0.70 SMN1; SMN2 (0.44) SMN1; SMN2TSHRNPC1RAB9ALMNA
SCHEMBL6652458 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA SMN1; SMN2 1864/4885PYGM 1856/4885GAA 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.